FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137043313> ?p ?o ?g. }

• W2137043313 endingPage "190" @default.
• W2137043313 startingPage "187" @default.
• W2137043313 abstract "Corticosteroid administration produces multiple immunomodulatory effects, including down-regulation of cytokine production by CD4 T lymphocytes. Fluticasone propionate (FP) (Glaxo Smith&Kline, Greenford, UK), a highly lipophilic topical corticosteroid, has been shown to be safe and effective in the treatment of asthma and of both seasonal and perennial rhinitis.To gain insight into the mechanisms of FP therapeutic effects, we evaluated interleukin (IL)-13 (a type 2 cytokine that seemingly plays a pivotal role in allergic mechanisms) production by mitogen-stimulated peripheral blood mononuclear cells (MNC) in vitro, treated or not with FP.MNC from 10 healthy subjects and 10 asthmatic atopic patients with Parietaria allergy were stimulated v/v with phytohaemagglutinin (PHA) (50 gamma/ml) or with complete medium alone as a control. Culture supernatants, in vitro treated or not with 10(-7) or 10(-8) M FP, were collected after 48 or 72 h incubation. IL-13 production was assessed by enzyme-linked immunosorbent assay. In random selected samples, after 4 or 24 h of cell cultures, RNA was extracted and IL-4 and IL-5 reverse transcriptase-polymerase chain reaction (RT-PCR) products analyzed.At 48 h, there were no differences in IL-13 concentration in PHA-stimulated cultures between healthy subjects and asthmatic patients (93.6 +/- 18.9 versus 111.0 +/- 25.1 pg/ml). At 72 h, similar results were obtained (63.9 +/- 3.0 versus 73.3 +/- 2.5 pg/ml, respectively). At this time, however, IL-13 concentrations were significantly decreased versus 48 h both in asthmatics (p < 0.001) and in controls (p < 0.001). Treatment with 10(-7) M FP significantly reduced IL-13 production in healthy subjects and asthmatic patients both at 48 h (93.6 +/- 18.9 versus 50.50 +/- 10.6 pg/ml, p < 0.001, and 111.0 +/- 25.1 versus 59.3 +/- 13.6 pg/ml, p < 0.001, respectively) and at 72 h (63.9 +/- 9.6 versus 35.5 +/- 4.4 pg/ml, p < 0.001, and 73.3 +/- 8.0 versus 40.7 +/- 4.5 pg/ml, p < 0.001, respectively). Similar results were obtained with 10(-8) M FP at 48 and 72 h. Accordingly, evaluation of RT-PCR products from selected cell samples showed a FP dosage-dependent inhibition of IL-4 and IL-5 mRNA production both for healthy subjects and asthmatic patients.FP in vitro impairs IL-13 production by PHA-stimulated MNC from asthmatic and control subjects. This strengthens previous suggestions that IL-13 inhibition by steroids may, at least in part, account for their therapeutic effects." @default.
• W2137043313 created "2016-06-24" @default.
• W2137043313 creator A5008627190 @default.
• W2137043313 creator A5011384792 @default.
• W2137043313 creator A5012951315 @default.
• W2137043313 creator A5015945590 @default.
• W2137043313 creator A5054433356 @default.
• W2137043313 creator A5058464702 @default.
• W2137043313 creator A5063776820 @default.
• W2137043313 creator A5067811540 @default.
• W2137043313 creator A5074863074 @default.
• W2137043313 date "2002-01-01" @default.
• W2137043313 modified "2023-10-16" @default.
• W2137043313 title "<i>In vitro</i>effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes" @default.
• W2137043313 cites W1896151710 @default.
• W2137043313 cites W1965520579 @default.
• W2137043313 cites W1966159794 @default.
• W2137043313 cites W1970501691 @default.
• W2137043313 cites W1975345757 @default.
• W2137043313 cites W1989772024 @default.
• W2137043313 cites W2016377904 @default.
• W2137043313 cites W2034297809 @default.
• W2137043313 cites W2043603230 @default.
• W2137043313 cites W2061362931 @default.
• W2137043313 cites W2075993468 @default.
• W2137043313 cites W2108836360 @default.
• W2137043313 cites W2114792473 @default.
• W2137043313 cites W2155345300 @default.
• W2137043313 cites W2161795345 @default.
• W2137043313 doi "https://doi.org/10.1080/09622935020138226" @default.
• W2137043313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1781657" @default.
• W2137043313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12137248" @default.
• W2137043313 hasPublicationYear "2002" @default.
• W2137043313 type Work @default.
• W2137043313 sameAs 2137043313 @default.
• W2137043313 citedByCount "9" @default.
• W2137043313 countsByYear W21370433132014 @default.
• W2137043313 countsByYear W21370433132019 @default.
• W2137043313 countsByYear W21370433132023 @default.
• W2137043313 crossrefType "journal-article" @default.
• W2137043313 hasAuthorship W2137043313A5008627190 @default.
• W2137043313 hasAuthorship W2137043313A5011384792 @default.
• W2137043313 hasAuthorship W2137043313A5012951315 @default.
• W2137043313 hasAuthorship W2137043313A5015945590 @default.
• W2137043313 hasAuthorship W2137043313A5054433356 @default.
• W2137043313 hasAuthorship W2137043313A5058464702 @default.
• W2137043313 hasAuthorship W2137043313A5063776820 @default.
• W2137043313 hasAuthorship W2137043313A5067811540 @default.
• W2137043313 hasAuthorship W2137043313A5074863074 @default.
• W2137043313 hasBestOaLocation W21370433131 @default.
• W2137043313 hasConcept C126322002 @default.
• W2137043313 hasConcept C134018914 @default.
• W2137043313 hasConcept C137061746 @default.
• W2137043313 hasConcept C185592680 @default.
• W2137043313 hasConcept C202751555 @default.
• W2137043313 hasConcept C203014093 @default.
• W2137043313 hasConcept C207480886 @default.
• W2137043313 hasConcept C25642318 @default.
• W2137043313 hasConcept C2776042228 @default.
• W2137043313 hasConcept C2776804153 @default.
• W2137043313 hasConcept C2777761686 @default.
• W2137043313 hasConcept C2778690821 @default.
• W2137043313 hasConcept C2779028295 @default.
• W2137043313 hasConcept C2780050583 @default.
• W2137043313 hasConcept C55493867 @default.
• W2137043313 hasConcept C71924100 @default.
• W2137043313 hasConcept C74172505 @default.
• W2137043313 hasConcept C98274493 @default.
• W2137043313 hasConceptScore W2137043313C126322002 @default.
• W2137043313 hasConceptScore W2137043313C134018914 @default.
• W2137043313 hasConceptScore W2137043313C137061746 @default.
• W2137043313 hasConceptScore W2137043313C185592680 @default.
• W2137043313 hasConceptScore W2137043313C202751555 @default.
• W2137043313 hasConceptScore W2137043313C203014093 @default.
• W2137043313 hasConceptScore W2137043313C207480886 @default.
• W2137043313 hasConceptScore W2137043313C25642318 @default.
• W2137043313 hasConceptScore W2137043313C2776042228 @default.
• W2137043313 hasConceptScore W2137043313C2776804153 @default.
• W2137043313 hasConceptScore W2137043313C2777761686 @default.
• W2137043313 hasConceptScore W2137043313C2778690821 @default.
• W2137043313 hasConceptScore W2137043313C2779028295 @default.
• W2137043313 hasConceptScore W2137043313C2780050583 @default.
• W2137043313 hasConceptScore W2137043313C55493867 @default.
• W2137043313 hasConceptScore W2137043313C71924100 @default.
• W2137043313 hasConceptScore W2137043313C74172505 @default.
• W2137043313 hasConceptScore W2137043313C98274493 @default.
• W2137043313 hasFunder F4320307773 @default.
• W2137043313 hasIssue "3" @default.
• W2137043313 hasLocation W21370433131 @default.
• W2137043313 hasLocation W21370433132 @default.
• W2137043313 hasLocation W21370433133 @default.
• W2137043313 hasLocation W21370433134 @default.
• W2137043313 hasLocation W21370433135 @default.
• W2137043313 hasOpenAccess W2137043313 @default.
• W2137043313 hasPrimaryLocation W21370433131 @default.
• W2137043313 hasRelatedWork W1975729558 @default.
• W2137043313 hasRelatedWork W1994050787 @default.
• W2137043313 hasRelatedWork W2025274024 @default.

• next